130 related articles for article (PubMed ID: 9728617)
21. Utility of glucose transporter 1 in the distinction of benign and malignant thoracic and abdominal mesothelial lesions.
Lagana SM; Taub RN; Borczuk AC
Arch Pathol Lab Med; 2012 Jul; 136(7):804-9. PubMed ID: 22742553
[TBL] [Abstract][Full Text] [Related]
22. Immunohistochemical differentiation of malignant mesothelioma, mesothelial hyperplasia and metastatic adenocarcinoma in serous effusions, utilizing staining for carcinoembryonic antigen, keratin and vimentin.
Duggan MA; Masters CB; Alexander F
Acta Cytol; 1987; 31(6):807-14. PubMed ID: 2447718
[TBL] [Abstract][Full Text] [Related]
23. Quantitative analysis of nucleoli and nucleolar organizer regions in cultured primary human normal, reactive and malignant mesothelial cells.
Ribotta M; Donna A; Betta PG; Libener R; Bellingeri D; Robutti F
Pathol Res Pract; 1992 Jun; 188(4-5):536-40. PubMed ID: 1409084
[TBL] [Abstract][Full Text] [Related]
24. Utility of AgNOR technique in distinguishing reactive mesothelial hyperplasia, malignant mesothelioma and pulmonary adenocarcinoma.
Ramesh K; Gahukamble L; al Fituri O
Cent Afr J Med; 1994 Sep; 40(9):265. PubMed ID: 7834719
[No Abstract] [Full Text] [Related]
25. Immunohistochemical detection of XIAP in mesothelium and mesothelial lesions.
Wu M; Sun Y; Li G; Desman G; Wang B; Gil J; Burstein DE
Am J Clin Pathol; 2007 Nov; 128(5):783-7. PubMed ID: 17951200
[TBL] [Abstract][Full Text] [Related]
26. The use of immunohistochemistry to distinguish reactive mesothelial cells from malignant mesothelioma in cytologic effusions.
Hasteh F; Lin GY; Weidner N; Michael CW
Cancer Cytopathol; 2010 Apr; 118(2):90-6. PubMed ID: 20209622
[TBL] [Abstract][Full Text] [Related]
27. The diagnostic value of Ki-67 and repp86 in distinguishing between benign and malignant mesothelial proliferations.
Taheri ZM; Mehrafza M; Mohammadi F; Khoddami M; Bahadori M; Masjedi MR
Arch Pathol Lab Med; 2008 Apr; 132(4):694-7. PubMed ID: 18384222
[TBL] [Abstract][Full Text] [Related]
28. Malignant mesothelioma eight years after a diagnosis of atypical mesothelial hyperplasia.
Scurry J; Duggan MA
J Clin Pathol; 1999 Jul; 52(7):535-7. PubMed ID: 10605410
[TBL] [Abstract][Full Text] [Related]
29. Immunohistological staining of reactive mesothelium, mesothelioma, and lung carcinoma with a panel of monoclonal antibodies.
Ghosh AK; Gatter KC; Dunnill MS; Mason DY
J Clin Pathol; 1987 Jan; 40(1):19-25. PubMed ID: 2434531
[TBL] [Abstract][Full Text] [Related]
30. p16 FISH deletion in surface epithelial mesothelial proliferations is predictive of underlying invasive mesothelioma.
Hwang H; Tse C; Rodriguez S; Gown A; Churg A
Am J Surg Pathol; 2014 May; 38(5):681-8. PubMed ID: 24503757
[TBL] [Abstract][Full Text] [Related]
31. The concept of mesothelioma in situ: implications for diagnosis and histogenesis.
Whitaker D; Henderson DW; Shilkin KB
Semin Diagn Pathol; 1992 May; 9(2):151-61. PubMed ID: 1609157
[TBL] [Abstract][Full Text] [Related]
32. A morphometrically-based classification rule for the diagnosis of primary mesothelial lesions.
Robutti F; Betta PG; Donna A; Pavesi M
J Pathol; 1990 Sep; 162(1):57-60. PubMed ID: 2231194
[TBL] [Abstract][Full Text] [Related]
33. [Thoracoscopic anatomy, significance of pathologic findings in thoracoscopic open lung biopsy, and pleural mesothelioma].
Kawai T; Watanabe M; Takagi K
Nihon Kyobu Shikkan Gakkai Zasshi; 1994 Dec; 32 Suppl():142-7. PubMed ID: 7602822
[TBL] [Abstract][Full Text] [Related]
34. The expression pattern of beta-catenin in mesothelial proliferative lesions and its diagnostic utilities.
Dai Y; Bedrossian CW; Michael CW
Diagn Cytopathol; 2005 Nov; 33(5):320-4. PubMed ID: 16240396
[TBL] [Abstract][Full Text] [Related]
35. [Nodular histiocytic/mesothelial hyperplasia: a clinicopathologic analysis of 7 cases].
Cai Z; Xie Q; Wang X; Guo B; Wang X; Wang K
Zhonghua Bing Li Xue Za Zhi; 2014 Apr; 43(4):256-9. PubMed ID: 24915817
[TBL] [Abstract][Full Text] [Related]
36. Use of antibodies to carcinoembryonic antigen and human milk fat globule to distinguish carcinoma, mesothelioma, and reactive mesothelium.
Marshall RJ; Herbert A; Braye SG; Jones DB
J Clin Pathol; 1984 Nov; 37(11):1215-21. PubMed ID: 6094617
[TBL] [Abstract][Full Text] [Related]
37. Immunoperoxidase localization of secretory component in reactive mesothelium and mesotheliomas.
Ernst CS; Brooks JJ
J Histochem Cytochem; 1981 Sep; 29(9):1102-4. PubMed ID: 7026669
[TBL] [Abstract][Full Text] [Related]
38. The separation of benign and malignant mesothelial proliferations.
Churg A; Galateau-Salle F
Arch Pathol Lab Med; 2012 Oct; 136(10):1217-26. PubMed ID: 23020727
[TBL] [Abstract][Full Text] [Related]
39. [Utility of morphometry and nucleolar organizer regions count in the differentiation of reactive and malignant mesothelial cells in pleural effusions].
Colecchia M; Agnelli T; Caronni E; Leopardi O
Pathologica; 1991; 83(1083):89-97. PubMed ID: 1866205
[TBL] [Abstract][Full Text] [Related]
40. Metastatic appendiceal mucinous adenocarcinoma to well-differentiated diffuse mesothelioma of the peritoneal cavity: a mimicker of florid mesothelial hyperplasia in association with neoplasms.
Tran TA; Holloway RW; Finkler NJ
Int J Gynecol Pathol; 2008 Oct; 27(4):526-30. PubMed ID: 18753969
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
